EA032642B1 - АНАЛОГИ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K - Google Patents

АНАЛОГИ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K Download PDF

Info

Publication number
EA032642B1
EA032642B1 EA201790016A EA201790016A EA032642B1 EA 032642 B1 EA032642 B1 EA 032642B1 EA 201790016 A EA201790016 A EA 201790016A EA 201790016 A EA201790016 A EA 201790016A EA 032642 B1 EA032642 B1 EA 032642B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
reaction
alkyl
mmol
acid
Prior art date
Application number
EA201790016A
Other languages
English (en)
Russian (ru)
Other versions
EA201790016A1 (ru
Inventor
Чжэнде У
Тао Юй
Шухуй Чжэнь
Original Assignee
ЧИА ТАЙ ТЯНЬЦИН ФАРМАСЬЮТИКАЛ ГРУП КО., эЛТиДи.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032642(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by ЧИА ТАЙ ТЯНЬЦИН ФАРМАСЬЮТИКАЛ ГРУП КО., эЛТиДи. filed Critical ЧИА ТАЙ ТЯНЬЦИН ФАРМАСЬЮТИКАЛ ГРУП КО., эЛТиДи.
Publication of EA201790016A1 publication Critical patent/EA201790016A1/ru
Publication of EA032642B1 publication Critical patent/EA032642B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201790016A 2014-06-17 2015-06-16 АНАЛОГИ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K EA032642B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201510324348 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (2)

Publication Number Publication Date
EA201790016A1 EA201790016A1 (ru) 2017-06-30
EA032642B1 true EA032642B1 (ru) 2019-06-28

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790016A EA032642B1 (ru) 2014-06-17 2015-06-16 АНАЛОГИ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602815B (zh) * 2015-12-16 2020-07-28 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US12325695B2 (en) * 2019-01-24 2025-06-10 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor
JP7765088B2 (ja) 2019-12-02 2025-11-06 ストーム・セラピューティクス・リミテッド Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
EP4095137A4 (en) * 2020-02-10 2024-03-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. USE OF A PYRIDO[1,2-A]PYRIMIDINONE COMPOUND FOR THE TREATMENT OF LYMPHOMAS
CN115135649A (zh) * 2020-03-10 2022-09-30 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
CN116323609A (zh) * 2020-09-15 2023-06-23 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
CN116761608A (zh) * 2020-12-08 2023-09-15 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369370T1 (de) * 2003-10-10 2007-08-15 Pfizer Prod Inc Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
MX315904B (es) * 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
CN103096977B (zh) * 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Also Published As

Publication number Publication date
CN106470992B (zh) 2018-11-06
TW201625612A (zh) 2016-07-16
US20170137420A1 (en) 2017-05-18
CA2951971C (en) 2024-09-10
KR20170016465A (ko) 2017-02-13
EA201790016A1 (ru) 2017-06-30
JP2017519821A (ja) 2017-07-20
CA2951971A1 (en) 2015-12-23
AU2015276699A1 (en) 2017-01-19
EP3159341A4 (en) 2018-05-16
EP3159341A1 (en) 2017-04-26
AU2015276699B2 (en) 2019-10-10
EP3159341B8 (en) 2020-01-08
KR102495840B1 (ko) 2023-02-03
CN106470992A (zh) 2017-03-01
TWI628180B (zh) 2018-07-01
ES2754264T3 (es) 2020-04-16
EP3159341B1 (en) 2019-08-21
JP6680774B2 (ja) 2020-04-15
US9856256B2 (en) 2018-01-02
WO2015192760A1 (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
EA032642B1 (ru) АНАЛОГИ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
TWI765908B (zh) 苯並咪唑類化合物激酶抑制劑及其製備方法和應用
WO2022061251A1 (en) Compounds and methods for kras modulation and indications therefor
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
ES2935114T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
TWI600655B (zh) 作為ｍＴＯＲ／ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物
ES2906205T3 (es) Inhibidor de Syk y método de uso para el mismo
EA019941B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2021226547A2 (en) Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
KR20190058678A (ko) c-MET 억제제로서의 피리돈계　화합물
KR20170113607A (ko) 9h-피롤로-디피리딘 유도체
EA016108B1 (ru) [2,6]нафтиридины, применимые в качестве ингибиторов протеинкиназы
KR20230175222A (ko) Nek7 억제제
US12338226B2 (en) Substituted benzodiazoles and use thereof in therapy
CN116023368A (zh) Crbn免疫调节剂
JP2022515309A (ja) 置換アリール化合物、その製造方法及び用途
CA2878481A1 (en) Method for preparing substituted triazolopyridines
KR20230131251A (ko) 키나아제 억제제로서의 인돌 유도체
AU2013403333A1 (en) Phenyl linked quinolinyl modulators of ROR-gamma-t
HK1238629B (zh) 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM